Celcuity Inc. CEO Brian Sullivan to Present at Investor Conferences

Author:

Celcuity Inc., a biotechnology company specializing in the development of targeted therapies for oncology, has announced that its Chief Executive Officer and Co-founder, Brian Sullivan, will be presenting at upcoming investor conferences. These conferences will provide an opportunity for one-on-one meetings with investors.

The live webcasts of the presentations will be available on the company’s website for those who are unable to attend in person. The webcasts will also have a replay option shortly after the live events.

Celcuity is currently focused on the development of targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate, gedatolisib, is a potent inhibitor of PI3K and mTOR. Its mechanism of action and pharmacokinetic properties set it apart from other therapies that target PI3K or mTOR alone or in combination.

The company is conducting a Phase 3 clinical trial, VIKTORIA-1, to evaluate gedatolisib in combination with fulvestrant with or without palbociclib for patients with HR+/HER2- advanced breast cancer. They are also enrolling patients for a Phase 1b/2 trial, CELC-G-201, to evaluate gedatolisib in combination with darolutamide for patients with metastatic castration-resistant prostate cancer.

Celcuity’s CELsignia companion diagnostic platform is able to analyze live patient tumor cells and identify new groups of cancer patients who may benefit from targeted therapies that are already approved.

Additional information about Celcuity and its ongoing clinical trials can be found on their website.

Celcuity Inc. operates in the biotechnology industry, specifically focusing on the development of targeted therapies for oncology. This industry is dedicated to finding innovative treatments for cancer by utilizing the latest advancements in biotechnology and molecular biology.

The market for targeted therapies in oncology has been growing rapidly in recent years. These therapies aim to precisely target cancer cells while minimizing damage to healthy cells, leading to more effective and less toxic treatment options for patients. According to market forecasts, the global oncology targeted therapy market is expected to reach a value of over $220 billion by 2026source.

One of the main challenges in the industry is identifying the specific genetic mutations and biomarkers that drive the development and progression of different types of cancer. Companies like Celcuity are focused on discovering these specific targets in order to develop therapies that can effectively inhibit or eradicate cancer cells based on their genetic profiles.

Celcuity’s lead therapeutic candidate, gedatolisib, is a promising targeted therapy that inhibits PI3K and mTOR, two proteins that play key roles in cancer cell growth and survival. By specifically targeting these proteins, gedatolisib has the potential to be more effective and have fewer side effects compared to other therapies that target PI3K or mTOR alone or in combination.

The company is currently conducting clinical trials to evaluate the safety and efficacy of gedatolisib in combination with other drugs for the treatment of advanced breast cancer and metastatic castration-resistant prostate cancer. These trials are important for assessing the potential of gedatolisib in these patient populations and for obtaining regulatory approval for its use in the future.

Celcuity’s CELsignia companion diagnostic platform is another innovative aspect of the company’s work. This platform allows for the analysis of live patient tumor cells to identify new groups of cancer patients who may benefit from targeted therapies that are already approved. By accurately identifying patients who are likely to respond to specific treatments, CELsignia can help optimize patient care and improve treatment outcomes.

For more information about Celcuity and its ongoing clinical trials, interested individuals can visit their website: www.celcuity.com.